A Retrospective Cohort Study of the 2018 Angiotensin Receptor Blocker Recalls and Subsequent Drug Shortages in Patients With Hypertension

A Retrospective Cohort Study of the 2018 Angiotensin Receptor Blocker Recalls and Subsequent Drug Shortages in Patients With Hypertension

Background Valsartan was recalled by the US Food and Drug Administration in July 2018 for carcinogenic impurities, resulting in a drug shortage and management challenges for valsartan users. The influence of the valsartan recall on clinical outcomes is unknown. We compared the risk of adverse events...

Full description

Bibliographic Details
Main Authors: Joshua W. Devine, Mina Tadrous, Inmaculada Hernandez, Katherine Callaway Kim, Scott D. Rothenberger, Nandita Mukhopadhyay, Walid F. Gellad, Katie J. Suda
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
drug recall
drug shortages
hypertension
valsartan
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.032266

Similar Items

Similar Items